The IPO market saw 10 companies price last week, bringing the year's total up to 134, which surpasses the 125 IPOs in 2011 and 128 in 2012. 18 companies have rallied to price this week before the second quarter ends and the short Independence Day week begins,...read more
ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5.9 million shares (vs. 5 million originally planned) at $18, above the $15 to $17 range. ZS Pharma will list on the NASDAQ under the...read more
ZS Pharma, a late-stage biotech developing a treatment for hyperkalemia, announced terms for its IPO on Friday. The Coppell, TX-based company plans to raise $80 million by offering 5.0 million shares at a price range of $15 to $17. At the midpoint of the...read more
US IPO Pricing Recap: IPO count surpasses 2011 and 2012 totals as Markit and 9 others go public
The IPO market saw 10 companies price last week, bringing the year's total up to 134, which surpasses the 125 IPOs in 2011 and 128 in 2012. 18 companies have rallied to price this week before the second quarter ends and the short Independence Day week begins,...read more
ZS Pharma prices IPO at $18, above the range
ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5.9 million shares (vs. 5 million originally planned) at $18, above the $15 to $17 range. ZS Pharma will list on the NASDAQ under the...read more
12 US IPOs planned for the week of Jun 16
The following IPOs are expected to price this week: Ardelyx (ARDX), a biotech developing small molecule treatments for kidney and gastrointestinal diseases, plans to...read more
Late-stage biotech ZS Pharma sets terms for $80 million IPO
ZS Pharma, a late-stage biotech developing a treatment for hyperkalemia, announced terms for its IPO on Friday. The Coppell, TX-based company plans to raise $80 million by offering 5.0 million shares at a price range of $15 to $17. At the midpoint of the...read more